[Congressional Record Volume 163, Number 5 (Monday, January 9, 2017)]
[Senate]
[Page S158]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 33. Ms. KLOBUCHAR (for herself, Ms. Hassan, and Mr. Van Hollen) 
submitted an amendment intended to be proposed by her to the concurrent 
resolution S. Con. Res. 3, setting forth the congressional budget for 
the United States Government for fiscal year 2017 and setting forth the 
appropriate budgetary levels for fiscal years 2018 through 2026; which 
was ordered to lie on the table; as follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO 
                   PRESCRIPTION DRUGS.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution 
     for one or more bills, joint resolutions, amendments, 
     amendments between the Houses, motions, or conference reports 
     relating to eliminating anticompetitive pay-for-delay patent 
     settlements between branded drug and generic drug 
     manufacturers that delay competition and increase 
     prescription drug costs by the amounts provided in such 
     legislation for those purposes, provided that such 
     legislation would not increase the deficit over either the 
     period of the total of fiscal years 2017 through 2021 or the 
     period of the total of fiscal years 2017 through 2026.
                                 ______